Reviewing Baxter International (NYSE:BAX) & Anteris Technologies Global (NASDAQ:AVR)
by Sarita Garza · The Markets DailyBaxter International (NYSE:BAX – Get Free Report) and Anteris Technologies Global (NASDAQ:AVR – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Baxter International and Anteris Technologies Global, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Baxter International | 2 | 9 | 2 | 0 | 2.00 |
| Anteris Technologies Global | 1 | 0 | 4 | 0 | 2.60 |
Baxter International currently has a consensus price target of $22.45, indicating a potential downside of 4.48%. Anteris Technologies Global has a consensus price target of $16.00, indicating a potential upside of 106.72%. Given Anteris Technologies Global’s stronger consensus rating and higher probable upside, analysts plainly believe Anteris Technologies Global is more favorable than Baxter International.
Volatility & Risk
Baxter International has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Anteris Technologies Global has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500.
Earnings & Valuation
This table compares Baxter International and Anteris Technologies Global”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Baxter International | $11.24 billion | 1.08 | -$957.00 million | ($2.07) | -11.36 |
| Anteris Technologies Global | $2.24 million | 336.45 | -$94.14 million | ($1.95) | -3.97 |
Anteris Technologies Global has lower revenue, but higher earnings than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
90.2% of Baxter International shares are owned by institutional investors. 0.2% of Baxter International shares are owned by insiders. Comparatively, 4.5% of Anteris Technologies Global shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Baxter International and Anteris Technologies Global’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Baxter International | -9.27% | 16.57% | 5.24% |
| Anteris Technologies Global | -4,619.27% | -77.69% | -67.99% |
Summary
Anteris Technologies Global beats Baxter International on 9 of the 14 factors compared between the two stocks.
About Baxter International
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company’s products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
About Anteris Technologies Global
Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.